NU-CEFUROXIME TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

CEFUROXIME (CEFUROXIME AXETIL)

제공처:

NU-PHARM INC

ATC 코드:

J01DC02

INN (International Name):

CEFUROXIME

복용량:

500MG

약제 형태:

TABLET

구성:

CEFUROXIME (CEFUROXIME AXETIL) 500MG

관리 경로:

ORAL

패키지 단위:

60/100/500

처방전 유형:

Prescription

치료 영역:

SECOND GENERATION CEPHALOSPORINS

제품 요약:

Active ingredient group (AIG) number: 0122448002; AHFS:

승인 상태:

CANCELLED (UNRETURNED ANNUAL)

승인 날짜:

2018-03-28

제품 특성 요약

Page 1 of 26
PRODUCT MONOGRAPH
PR
NU-CEFUROXIME
CEFUROXIME AXETIL TABLETS
250 MG AND 500 MG CEFUROXIME/TABLET
NU-PHARM STANDARD
ANTIBIOTIC
NU-PHARM INC.
DATE OF PREPARATION:
50 MURAL ST., UNITS 1 & 2
OCTOBER 20, 2009
RICHMOND HILL, ONTARIO
L4B 1E4
CONTROL#: 133377
Page 2 of 26
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................3
SUMMARY PRODUCT
INFORMATION.................................................................................3
INDICATIONS AND CLINICAL
USE.......................................................................................3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND
PRECAUTIONS.........................................................................................4
ADVERSE REACTIONS
.........................................................................................................5
DRUG
INTERACTIONS..........................................................................................................6
DOSAGE AND
ADMINISTRATION.........................................................................................6
OVERDOSAGE.......................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................7
STORAGE AND STABILITY
...................................................................................................7
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................7
PART II: SCIENTIFIC
INFORMATION.......................................................................................9
PHARMACEUTICAL
INFORMATION.....................................................................................9
CLINICAL
TRIALS.......................................................................................................